Bringing the Oncology Community Together

Dr. Goy on Novel Therapies at the JTCC Conference

Andre Goy, MD, MS
Published Online: Tuesday, October 11, 2011


Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”

Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming New Frontiers In The Management of Solid and Liquid Tumors conference at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011.

Related Articles
The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.
A treatment regimen rooted in traditional Chinese philosophy has emerged as a targeted approach for patients with newly diagnosed, lower-risk acute promyelocytic leukemia.
On Sunday, December 9, 2012, the Plenary Session at the 54th American Society of Hematology Annual Meeting featured several noteworthy abstracts.
Most Popular Right Now
Physicians' Education Resource
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedHC
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2013
Intellisphere, LLC. All Rights Reserved.